100 King Street West
Suite 5600
Toronto, ON M5X 1C9
Canada
https://www.cybin.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 50
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman | 457,42k | N/D | 1976 |
Mr. Douglas L. Drysdale | Chief Executive Officer | 611,49k | N/D | 1970 |
Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director | 457,42k | N/D | 1989 |
Mr. Greg Cavers | Chief Financial Officer | 241,32k | N/D | 1971 |
Mr. Aaron Bartlone | Chief Operating Officer | 377,91k | N/D | N/D |
Mr. John Kanakis | Co-Founder | 701,79k | N/D | 1980 |
Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer | N/D | N/D | 1960 |
Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer | N/D | N/D | N/D |
Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary | N/D | N/D | 1976 |
Sara Brittany Somerset | Chief Communications Officers | N/D | N/D | N/D |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.
L'ISS Governance QualityScore di Cybin Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.